Cyprotex Offers Solvo Biotechnology’s Drug Transporter Services
Firms claim services will support FDA recommendations on pre-IND data requirements.!--h2>
Preclinical CRO Cyprotex and Solvo Biotechnology have established a partnership that will allow Cyprotex to offer Solvo’s drug transporter services to its clients alongside its existing ADME and toxicology services. The firms say the move will help comply with recommendations published last year by the FDA-established International Transporter Consortium, which set standards for including drug transporter assays in existing preclinical ADME and toxicology assessments.
“The recommendations of the International Transporter Consortium for including drug-transporter assays among the other ADME tox assays needed prior to filing for IND status have dramatically increased demand from drug-discovery companies wanting to include transporter assays along wtih their other ADME tox assays,” comments Erno Duda, Solvo’s CEO. “Our partnership with Cyprotex makes it easy for Cyprotex’ ADME Tox customers to include transporter assays along with other ADME Tox assays they need.” U.K.-based Cyprotex offers a wide range of standard and tailored experimental and computational ADMET/PK and toxicology services, for early drug discovery through to IND submission.
Established in 1999, Hungarian firm Solvo specializes in the development and commercialization of membrane transporter technologies, diagnostics, and drug discovery assays. The firm’s primary products and services comprise in vitro and in vivo assay systems for detecting the interaction of compound candidates with a wide range of ABC and SLC transporter proteins for ADME/tox research. The service portfolio covers assays for all efflux and uptake transporters recommended by FDA, and includes transporter-specific in vivo rat brain microdialyis and rat liver biliary excretion assays.
The firm says it averages 10-15 new product and service launches annually. In March the firm introduced a family of Predicell™ kits, which it claims is the first commercially available ready-to-use uptake transporter assay platform for OATP1B3, OATP1B1, and OCT2. Predicell is available as a 96-well kit for inhibition studies, and a 24-well kit for direct uptake studies.